March 3, 2026Open Access

Impact of 18 FDG-avidity and immunosuppression on idiopathic and genetic cardiomyopathies

Puntos clave

Adverse heart failure outcomes are linked to 18 FDG-avidity in genotype-negative patients without clear inflammation.
Heart failure and arrhythmia outcomes were significantly worse for those with myocardial-only 18 FDG-avidity, suggesting a clinical concern.
Observational analysis highlights the role of 18 FDG uptake in identifying patients with potential adverse outcomes.
Immunosuppressive therapy does not appear to influence the disease progression, raising questions on its utility in these cases.

Resumen

Myocardial-only 18 FDG-avidity is only associated with adverse HF and arrhythmia outcomes in genotype-negative patients who do not clearly have CS. IST does not seem to modify the disease course, suggesting that not all myocardial 18 FDG uptake reflects clinically significant inflammation.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Institutions

University of Washington

Brigham and Women's Hospital

Oregon Health & Science University

References and Citations

Add This Paper to Your Research Feed

Any time a new paper drops it will be there.